SGLT2 Inhibitors and Effects on Hematopoiesis, Inflammation and Metabolic Markers (SGLT2HgB)

University of Patras

Status: Active, not recruiting

Conditions: Diabetes Mellitus, Type 2

Treatments: Drug: SGLT2 inhibitor

Study type: Observational

Funder types: Other

Identifiers

NCT05408936

59/15.02.2022

Details and patient eligibility

About

Study of the response to SGLT2 inhibitors in type 2 diabetic patients with relevance to the erythropoesis and indexes of cardiorenal function.

The study enrolls type 2 diabetic patients in whom the introduction of a SGLT2 inhibitor is deemed necessary as part of their routine treatment during their visit to our outpatient diabetes unit.

A whole blood, a serum and a urine sample is obtained before and one month after the initiation of treatment with a SGLT2 inhibitor.

Enrollment: 80 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• type 2 diabetes
• Hba1C>7% on their current treatment
• introduction of SGLT2 inhibitor as part of their routine care

Exclusion criteria

• eGFR<60 ml/min